医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

World’s-First Tonsil Epithelial Organoids Model for SARS-CoV-2 Infection Published in Biomaterials

2022年04月04日 PM09:00
このエントリーをはてなブックマークに追加


 

PANGYO, South Korea

Organoids, in vitro miniaturized model systems of organs, has been positioned as the most advanced scientific technology for understanding disease progress mechanisms and for discovering novel drugs. However, the generation of tonsil organoids with high reproducibility had remained a technical challenge due to the lack of their cultural system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005434/en/

World’s-first tonsil epithelial organoids model for SARS-CoV-2 infection published in Biomaterials. The research team led by Professor Jongman Yoo (Cha University and CEO of ORGANOIDSCIENCES) along with Professor Young-Chang Lim (Konkuk University) and Dr. Meehyein Kim (Korea Research Institute of Chemical Technology) established tonsil epithelial cell-derived organoids and proved their feasibility as a 3D cultured infection model. (Graphic: Business Wire)

World’s-first tonsil epithelial organoids model for SARS-CoV-2 infection published in Biomaterials. The research team led by Professor Jongman Yoo (Cha University and CEO of ORGANOIDSCIENCES) along with Professor Young-Chang Lim (Konkuk University) and Dr. Meehyein Kim (Korea Research Institute of Chemical Technology) established tonsil epithelial cell-derived organoids and proved their feasibility as a 3D cultured infection model. (Graphic: Business Wire)

The research team led by Professor Jongman Yoo (Cha University and CEO of ORGANOIDSCIENCES) along with Professor Young-Chang Lim (Konkuk University) and Dr. Meehyein Kim (Korea Research Institute of Chemical Technology) successfully established tonsil epithelial cell-derived organoids and proved their feasibility as a 3D cultured infection model.

This is the first research outcome to the generation of tonsil epithelial organoids, which are structurally and genetically similar to human tonsil tissues, as well as to the scientific assessment of their suitability as an ex vivo model for SARS-CoV-2.

The team showed that the organoids elicit robust expression of transmembrane serine protease 2 (TMPRSS2) and furin, which are important for the maturation of spike proteins, and of the angiotensin-converting enzyme 2 (ACE2) cell surface receptor, which is essential for SARS-CoV-2 infection.

According to the journal, when Remdesivir, an antiviral drug, was applied to tonsil organoids infected with SARS-CoV-2, both viral RNA and protein levels were remarkably reduced. It is expected that the tonsil epithelial organoid could be utilized more extensively as an antiviral drug evaluation system for translational research, particularly against SARS-CoV-2 or its variants.

The results of this study demonstrated that the organoids are an attractive infection model for testing tissue susceptibility or transmissibility of diverse gastrointestinal or respiratory viruses. They provided insight into host defense mechanisms in terms of innate and adaptive immunity in which immunological interactions occur between tonsil epithelial cells, immune cells, and SARS-CoV-2.

The research team said, “Our discovery confirmative suggests that tonsil organoids can be one of the powerful platform technologies to find an antiviral drug against this pandemic virus. We hope our result can be connected to its applications in the research area of infectious diseases threatening public health such as COVID-19.”

Full research ‘Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection’ in Biomaterials:
https://reader.elsevier.com/reader/sd/pii/S0142961222000990?token=3C50A0FF12B65F8D8E0AC6754139E7136771454E45D1F8FEF43AF4AD9B9D81A1FC956E27A56B6931E1F9B7F92B442BBF&originRegion=us-east-1&originCreation=20220404043530

View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005434/en/

CONTACT

ORGANOIDSCIENCES

Sung-jun Jo

+82-31-707-2024

pr@organoidrx.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024